Please assess the completion status of the following clinical trial:

Trial Title: Markers of Pubertal Suppression During Therapy for Precocious Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age: 3 to 9 years old, inclusive~* Diagnosis of Central Precocious or Rapidly Progressive Puberty~* Bone Age more than 1 year advanced (obtained within 6 months of screening) AND~* Breasts Tanner II or greater AND~* One of the following:~* Random LH \> 1 mIU/mL~* Leuprolide-stimulated LH \> 4 mIU/mL~* Random estradiol \> 20 pg/mL~* Leuprolide-stimulated 24 hour estradiol \>20 pg/mL~* Naïve to GnRHa therapy~* Approved to receive Supprelin LA® therapy~* Have an acceptable surrogate capable of giving consent on the subject's behalf.~Exclusion Criteria:~* Previous GnRHa therapy~* Presence of peripheral precocious puberty including CAH

- Gender: FEMALE
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Children with Central Precocious Puberty (Type: None): Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.

Based on this trial design, predict the completion outcome and termination type (if applicable).